- Home
- XP vs PCVX Comparison
XP vs PCVX Comparison
Compare XP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | PCVX |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.0B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XP | PCVX |
|---|---|---|
| Price | $19.55 | $60.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $23.17 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 5.2M | 1.1M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.00 | N/A |
| Revenue Next Year | $13.64 | N/A |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.51 | $28.09 |
| 52 Week High | $23.13 | $65.00 |
Technical Indicators
Market Signals| Indicator | XP | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 53.99 |
| Support Level | $18.58 | $52.04 |
| Resistance Level | $20.42 | $65.00 |
| Average True Range (ATR) | 0.75 | 2.16 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 37.45 | 51.54 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.